ACSS2 and urinary bladder cancer: Further studies have shown that ACSS2 but not the established ACLY promotes tumor resistance to cisplatin by providing acetyl-CoA to cisplatin-resistant bladder cancer cells via glucose-derived endogenous acetate [99].